Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B
نویسندگان
چکیده
منابع مشابه
Successful low dose immune tolerance induction in severe haemophilia A with inhibitors below 40 Bethesda Units.
Different regimens are used to achieve immune tolerance in patients with severe haemophilia A and inhibitory allo-antibodies against factor VIII (FVIII). In this study, results of 26 years of low dose immune tolerance induction are evaluated. We evaluated 21 patients, who were treated with regular infusions of low dose FVIII (25-50 IU kg(-1) every other day or three times a week) to obtain immu...
متن کاملImmune tolerance induction in 31 children with haemophilia A: is ITI less successful in African Americans?
Inhibitor development continues to be a major problem in the treatment of haemophilia. Immune tolerance induction (ITI) continues to be the most effective approach to managing this complication. This study reviews the practice and outcome of ITI at a single centre over a 17-year period. All 31 inhibitor patients have haemophilia A. Two patients with haemophilia A underwent two trials of ITI and...
متن کاملExperience with a third generation recombinant factor VIII concentrate (Advate) for immune tolerance induction in patients with haemophilia A.
The development of an inhibitor represents one of the most challenging complications in patients with haemophilia A. Optimal management is immune tolerance induction (ITI), typically through the administration of high doses of factor VIII (FVIII) concentrate. Among 12 patients who underwent ITI using Advate, a third-generation recombinant FVIII product that is free of animal and human protein a...
متن کاملImmune tolerance induction with recombinant factor VIII in hemophilia A patients with high responding inhibitors.
Immune tolerance induction (ITI) eradicates inhibitors in patients with hemophilia A. This study was designed to investigate the success rate of ITI in high-responding inhibitor patients with severe hemophilia A using recombinant factor VIII (rFVIII). Twenty-six patients received different ITI regimens until a normal recovery (>66%) and half-life (>6 h) of infused FVIII was achieved. In order t...
متن کاملImmune tolerance induction in patients with severe hemophilia A with inhibitors
BACKGROUND Inhibitory antibodies to factor VIII (FVIII) are an important complication when managing patients with hemophilia A. Immune tolerance induction (ITI) has been regarded as a useful method for eradicating inhibitors. We report the results of a retrospective study in Korean patients with hemophilia A who underwent ITI. METHODS We reviewed the records of patients with hemophilia A with...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cochrane Database of Systematic Reviews
سال: 2014
ISSN: 1465-1858
DOI: 10.1002/14651858.cd010561.pub2